Kailera Plans IPO for Obesity Drug That Could Top Lilly’s Zepbound (March 30, 2026) by Frank Vinluan Kailera Therapeutics’ planned IPO will fund ongoing clinical development of a pipeline led by a drug that could rival Eli Lilly’s Zepbound in both efficacy and tolerability. Meanwhile, Renaissance Capital’s recap of first quarter 2026 IPOs shows slowing activity amid market turbulence from

Insilico Medicine secures $2.75 billion drug collaboration with Eli Lilly (March 29, 2026) by Reuters In March 2026, Eli Lilly signed a global licensing deal worth up to $2.75 billion. The partnership utilizes Insilico’s AI platform to develop novel oral therapeutics, including a preclinical GLP-1 candidate for diabetes.Eli Lilly & Insilico Medicine: A $2.75 Billion Strategic AI-Driven Partnership Pharmaceutical companies

Drug developer Generate Biomedicines raises $400 million in US IPO (February 26, 2026) by Reuters Founded by Flagship in 2018, Generate Biomedicines uses AI-driven technology to move beyond traditional trial-and-error drug discovery and develop new protein-based therapies, with its pipeline centered on immunology and oncology. Generate’s lead drug candidate for severe asthma, GB-0895, is currently in a late-stage trial, with

Boehringer Ingelheim licenses novel oral therapeutics program for immune diseases from Sitryx Therapeutics (Ingelheim, Germany, Oxford, UK, and Boston, USA, Feb 26, 2026) by Linda Ruckel and Dr Reinhard Malin. The preclinical, small molecule program offers a potential first-in-class, oral, precision immunometabolic approach to modulating disease-driving immune cells Deal includes upfront and milestone payments to Sitryx totaling over US $500

Roche obesity drug shows 22.5% weight loss as it seeks to catch up with Lilly, Novo (Jan 27, 2026) by Reuters. BERLIN, Jan 27 (Reuters) – Roche’s experimental obesity drug, which works in a similar way to Eli Lilly’s Zepbound, produced as much as 22.5% weight loss in a mid-stage trial, underpinning the Swiss drugmaker’s efforts to catch up with

In Structure licensing deal, Roche commits $100M to shore up GLP-1 position (March 30, 2026) by Angus Liu Disclosed in January 2026, Roche paid $100 million for a nonexclusive license to patents from Structure Therapeutics. This strategic move protects Roche’s oral GLP-1 candidate, CT-996, from potential patent litigation. Read More

Adaptive signs deal with Pfizer worth up to $890 million for rheumatoid arthritis research (Dec 15, 2025) by Reuters. Adaptive said it will earn up to $890 million for the rheumatoid arthritis asset, including upfront fees and milestone payments tied to research progress, product development, and sales. Pfizer will use Adaptive’s technology to analyze immune cells from rheumatoid arthritis patients

Novartis pens $1.7B immuno-dermatology pact with AI-enabled British biotech (Dec 9, 2025) by James Waldron . What we do know is that Novartis will hand over $55 million, spread across an upfront cash payment, an equity investment and additional R&D funding. Down the line, Relation is eligible to receive preclinical, development, regulatory and commercial sales milestones that could reach $1.7

Pfizer Enters into Exclusive Collaboration and License Agreement with YaoPharma (March 30, 2026) by Pfizer Media Relations Following its $10 billion acquisition of Metsera, Pfizer expanded its strategy in late 2025/early 2026 by collaborating with YaoPharma. The deal includes $150 million upfront for a GLP-1 drug in early development, with total milestones reaching $1.9 billion. Read More

Regeneron pledges more than $1B biobucks for ModeX multispecific antibodies (Oct 22, 2025) by Darren Incorvaia. Regeneron is buying in to Modex Therapeutics’ next-generation antibody platform with a $7 million upfront payment and a total potential deal value exceeding $1 billion. The New York-based biopharma will provide binders that ModeX will pair with its platform to fashion new multispecific antibodies